Detalhe da pesquisa
1.
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors.
Bioorg Med Chem Lett
; 43: 128058, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33895276
2.
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator.
J Med Chem
; 67(7): 5259-5271, 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38530741
3.
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.
Clin Cancer Res
; 29(23): 4870-4882, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37733811
4.
A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Clin Cancer Res
; 29(24): 5155-5172, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37982738
5.
Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors.
Pharmaceutics
; 14(10)2022 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36297668
6.
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Mol Cancer Ther
; 19(4): 988-998, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32241872
7.
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Cancer Immunol Res
; 8(10): 1300-1310, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32873605
8.
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
Anticancer Res
; 29(6): 1999-2007, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19528458
9.
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.
Bioorg Med Chem
; 17(2): 731-40, 2009 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19101155
10.
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Clin Cancer Res
; 25(23): 7175-7188, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409612
11.
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Clin Cancer Res
; 24(4): 847-857, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191969
12.
Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866156
13.
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
J Immunother Cancer
; 6(1): 45, 2018 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866166
14.
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
J Immunother Cancer
; 6(1): 31, 2018 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29712568
15.
Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor.
Mol Cancer Res
; 13(12): 1615-26, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26263910
16.
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
MAbs
; 7(5): 931-45, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26073904
17.
A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.
Cancer Biol Ther
; 15(9): 1208-18, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24921944
18.
Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.
MAbs
; 5(3): 418-31, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23567210
19.
Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Neoplasia
; 13(1): 49-59, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21245940
20.
Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
Methods Mol Biol
; 602: 235-52, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20012402